Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapiesПодробнее

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of lifeПодробнее

Sandip Patel, MD | Perspective on Cancer Care in the Time of COVID-19Подробнее

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agentsПодробнее

Managing Acute Immune Complications | Krina Patel, MD | IMS 2023Подробнее

Copy of Dr. Patel on Novel Agents for Patients With NSCLCПодробнее

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse eventsПодробнее

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse eventsПодробнее

Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLCПодробнее

Novel Cancer Immunotherapeutics: New Targets, New Combinations - Sandip Patel, UCSDПодробнее

Sandip Patel, MD - UCSD - June "Researcher of the Month"Подробнее

Lung Cancer Video Library - Combinations of Immunotherapy Agents in Advanced NSCLC: Current StatusПодробнее

Managing toxicities associated with immune-checkpoint inhibitorsПодробнее

Sandip Patel, MD | Addressing Patients on Cancer Care in the Time of COVID-19Подробнее

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019Подробнее

Lung Cancer Video Library - Evolving Standards for Molecular Testing in Advanced NSCLCПодробнее

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1Подробнее

NSCLC: Immunotherapy Toxicity ManagementПодробнее

Dr. Patel Discusses Impact of Immunotherapy on NSCLCПодробнее